Accuray Incorporated (ARAY): Price and Financial Metrics
ARAY Price/Volume Stats
| Current price | $2.17 | 52-week high | $3.10 |
| Prev. close | $2.19 | 52-week low | $1.40 |
| Day low | $2.16 | Volume | 373,008 |
| Day high | $2.23 | Avg. volume | 662,101 |
| 50-day MA | $1.94 | Dividend yield | N/A |
| 200-day MA | $2.24 | Market Cap | 215.36M |
ARAY Stock Price Chart Interactive Chart >
Accuray Incorporated (ARAY) Company Bio
Accuray Inc. designs, develops, and sells radio-surgery and radiation therapy systems for the treatment of tumors in the body. It offers the CyberKnife System, a robotic stereotactic radio-surgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. The company was founded in 1990 and is based in Sunnyvale, California.
Latest ARAY News From Around the Web
Below are the latest news stories about ACCURAY INC that investors may wish to consider to help them evaluate ARAY as an investment opportunity.
Accuray (ARAY) Launches VitalHold in Japan for Use With RadixactAccuray's (ARAY) VitalHold is likely to transform breast cancer treatment in Japan by integrating SGRT for precise radiotherapy. It may become a game-changer for patients and medical staff. |
Accuray Initiates Sales of the VitalHold™ Solution in Japan, Supporting Surface-guided Radiation Therapy on the Radixact® SystemAccuray Incorporated (NASDAQ: ARAY) announced today that the company has initiated sales of the VitalHold™* package supporting surface-guided radiation therapy (SGRT) on the Radixact® System in Japan beginning November 30, 2023. The VitalHold feature incorporates SGRT capability on the Radixact System using the Catalyst+ HD system manufactured by C-RAD, making it possible to deliver deep inspiration breath hold (DIBH) treatments, primarily for breast cancers, and perform markerless patient setup |
Insider Sell Alert: President Suzanne Winter Sells 65,390 Shares of Accuray Inc (ARAY)Accuray Incorporated (NASDAQ:ARAY), a company specializing in the development, manufacturing, and selling of radiotherapy systems for alternative cancer treatments, has recently witnessed a significant insider sell from one of its top executives. |
Accuray Incorporated (NASDAQ:ARAY) Q1 2024 Earnings Call TranscriptAccuray Incorporated (NASDAQ:ARAY) Q1 2024 Earnings Call Transcript November 7, 2023 Accuray Incorporated reports earnings inline with expectations. Reported EPS is $-0.03 EPS, expectations were $-0.03. Operator: Good afternoon and welcome to the Accuray’s First Quarter 2024 Conference Call. [Operator Instructions] Please note that this event is being recorded. I would now like to turn […] |
Accuray (ARAY) Q1 Earnings In-Line With Estimates, Revenues TopAccuray (ARAY) reports a solid fiscal first quarter top line on the back of robust Product revenues. |
ARAY Price Returns
| 1-mo | -5.24% |
| 3-mo | 24.71% |
| 6-mo | -16.54% |
| 1-year | -20.51% |
| 3-year | -41.82% |
| 5-year | -25.68% |
| YTD | -23.32% |
| 2023 | 35.41% |
| 2022 | -56.18% |
| 2021 | 14.39% |
| 2020 | 47.87% |
| 2019 | -17.30% |
Continue Researching ARAY
Want to see what other sources are saying about Accuray Inc's financials and stock price? Try the links below:Accuray Inc (ARAY) Stock Price | Nasdaq
Accuray Inc (ARAY) Stock Quote, History and News - Yahoo Finance
Accuray Inc (ARAY) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...